Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| UNIQURE | 8 | - | -2,59 % | ||
| DENALI THERAPEUTICS | 8 | - | +1,16 % | ||
| BIONTECH | 5 | 13 | +0,85 % | ||
| AVADEL PHARMACEUTICALS | 5 | 6 | -1,63 % | ||
| ORIC PHARMACEUTICALS | 4 | 2 | +1,02 % | ||
| VANDA PHARMACEUTICALS | 4 | - | +0,89 % | ||
| ROYALTY PHARMA | 4 | - | +0,09 % | ||
| PRAXIS PRECISION MEDICINES | 4 | - | 0,00 % | ||
| CUREVAC | 3 | 9 | -1,77 % | ||
| VERTEX PHARMACEUTICALS | 3 | 5 | -0,52 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | Morgen-Update: Curevac-Aktie stabil - Marktbeobachter rechnen mit Bewegung. | Hebelschein-Spekulant | |||
| 07:06 | ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 | 1 | GlobeNewswire (USA) | ||
| 05:42 | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | 217 | AFX News | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| 03:48 | ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 | 1 | GlobeNewswire (USA) | ||
| 01:06 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance | 481 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance... ► Artikel lesen | |
| 00:01 | Vanda jumps as FDA lifts tradipitant partial clinical hold | 6 | Seeking Alpha | ||
| Do | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| Do | FDA lifts partial clinical hold on Vanda's tradipitant for motion sickness | 3 | Investing.com | ||
| Do | Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Do | Wirksamkeit bestätigt: Aktie von Praxis Precision Medicines steigt nach vorzeitigem Studienabbruch sprunghaft an | 2 | Investing.com Deutsch | ||
| Do | Praxis Precision Medicines kommt Zulassung für Tremor-Medikament näher | 1 | Investing.com Deutsch | ||
| Do | Vanda Pharmaceuticals Inc.: FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness | 10 | PR Newswire | WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the... ► Artikel lesen | |
| Do | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies | 28 | GlobeNewswire (Europe) | Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting... ► Artikel lesen | |
| Do | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Do | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor | 12 | GlobeNewswire (Europe) | BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| Do | 1 Reason I'll Never Sell Vertex Pharmaceuticals Stock | 6 | The Motley Fool | ||
| Do | Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst | 1 | Benzinga.com | ||
| Do | BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory | 9 | Insider Monkey | ||
| Do | Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda | 6 | Seeking Alpha | ||
| Do | How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter | 13 | Investor's Business Daily |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .